Johnson & Johnson: In advanced prostate cancer, its investigational pasritamig-based immunological combination therapy showed a 73% PSA remission rate.

Zhitongcaijing · 1d ago
Johnson & Johnson: In advanced prostate cancer, its investigational pasritamig-based immunological combination therapy showed a 73% PSA remission rate.